ClinicalTrials.gg
Not yet recruitingNCT07826806Updated Sep 17, 2026

Efficacy and Safety of Anrikefon Injection for the Treatment of Postoperative Pain in Patients Undergoing Laparoscopic Hepatectomy

A Phase 2 interventional study of Anrikefon Injection and Flurbiprofen in Pain Management, sponsored by Tianjin Medical University Cancer Institute and Hospital. Not yet recruiting. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-09-17.

Sponsored by Tianjin Medical University Cancer Institute and Hospital · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Efficacy and safety of Anrikefon injection for the treatment of postoperative pain in patients undergoing laparoscopic hepatectomy--A single-center, randomized, controlled clinical study

02

Conditions studied

  • Pain Management

Keywords

  • Post-surgery,pain
03

In context

Lead sponsor

Tianjin Medical University Cancer Institute and Hospital is the lead sponsor of 495 studies on the registry; 294 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age between 18 and 75 years, any gender;
  2. (ASA) score of I or II;
  3. between 18 kg/m² and 30 kg/m²;
  4. Patients scheduled for laparoscopic liver resection under general anesthesia, with surgery lasting less than 6 hours;
  5. Surgical incision less than 10 cm;
  6. Able to understand pain intensity assessment methods.

Participants understand the purpose and procedures of this study, voluntarily participate, and sign a written form.

Exclusion criteria

Exclusion Criteria:

  1. Patients allergic to opioids, flurbiprofen ester, or any other ingredients in the drugs.
  2. Patients expected to use continuous epidural analgesia or local block analgesia during the treatment period.
  3. Patients with a history of gastrointestinal ulcers or bleeding who need treatment.
  4. Patients undergoing emergency surgery or trauma.
  5. Patients whose surgery needs to be converted to open abdominal surgery.
  6. Patients unwilling to use patient-controlled intravenous analgesia (PCIA).
  7. Patients with a history of upper abdominal surgery.
  8. Patients expected to require postoperative continued intubation.
  9. Patients needing postoperative admission to the ICU.
  10. Patients with any of the following disease history or evidence before screening:
  11. Severe cardiovascular or pulmonary diseases (myocardial infarction, heart failure, or respiratory failure).
  12. Neurological or psychiatric history: brain injury, intracranial hypertension, schizophrenia, mania, etc., judged by the investigator as not suitable for the study.
  13. History of digestive diseases: intestinal obstruction or other digestive system diseases that may cause nausea or vomiting as judged by the investigator; accompanied by other severe digestive tract issues affecting digestion (e.g., severe constipation, duodenal stasis syndrome, etc.), or other digestive diseases evaluated by the investigator as unsuitable for the study.
  14. Patients with obvious chronic dizziness or diagnosed vestibular function disorders (other than motion sickness), including but not limited to peripheral vestibular syndrome or central vestibular syndrome.
  15. Patients who received treatment before surgery.
  16. Patients who experienced nausea, retching, or vomiting within 24 hours before anesthesia induction (excluding bowel prep-related cases).
  17. Known allergy or to other anesthetics or antiemetics that may be used during the trial.
  18. Patients who used drugs with unclear half-lives that have analgesic or antiemetic effects within 14 days before randomization, or whose last use was less than 5 half-lives or the drug's effective duration (whichever is longer), including but not limited to opioids, non-opioid analgesics, antiemetics (or drugs with antiemetic effects), sedatives, anesthetics, , and other similar drugs.
  19. Patients needing dialysis or who have alcoholism during treatment.
  20. Pregnant or breastfeeding women, or those planning pregnancy during the study period or within 3 months after study completion.
  21. Subjects the investigator believes have any other factor making them unsuitable for this clinical study.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Experimental
    Anruikefen

    Drug: Anrikefon Injection

  • Placebo comparator
    Flurbiprofen Ester

    Drug: Flurbiprofen

Interventions

  • For patients undergoing laparoscopic liver resection, randomization is completed within 2 hours after surgery. Within 30 minutes after successful randomization, they receive their first injection of either Anruikefen or Flurbiprofen Ester. After the first dose, at 8±1h, 16±1h, 24±1h, 32±1h, 40±1h, 48±1h, 56±1h, and 64±1h, each participant is given a corresponding dose of Anruikefen IV infusion

  • DrugFlurbiprofen

    For patients undergoing laparoscopic liver resection, randomization is completed within 2 hours after surgery. Within 30 minutes after successful randomization, they receive their first injection of either Anruikefen or Flurbiprofen Ester. After the first dose, at 8±1h, 16±1h, 24±1h, 32±1h, 40±1h, 48±1h, 56±1h, and 64±1h, each participant is given a corresponding dose of Flurbiprofen Ester IV infusion.

06

What researchers measure

Primary outcomes

  1. 1. Area under the NRS pain score curve 24 hours after medication (AUC-NRS24)

    Time frame: 24 hours after surgery

Secondary outcomes

  1. Pain intensity at rest and during movement (assess pain scores at 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h after the first dose).

    Time frame: 0-72 hours after surgery

  2. Pain intensity difference (PID) at 30 min, 1, 3, 6, 12, 24, 48, and 72 h after dosing. Pain was assessed by NRS (0-10; 0=no pain, 10=severe pain). PID = baseline score (pre-dose/pre-op, 0 h) minus score at each time point. Unit: points.

    Time frame: 0-72 hours after surgery

  3. Sum of Pain Intensity Difference (SPID) at 30 min, 1, 3, 6, 12, 24, 48, and 72 h post-dose. NRS (0-10; 0=no pain, 10=worst pain) assessed pain. TPID = baseline score (pre-dose, 0 h) - score at each time point. Unit: points.

    Time frame: 0-72 hours after surgery

  4. Total Sufentanil dose administered via PCIA pump within 24 hours post-surgery. Measurement tool: PCIA pump (or electronic medical record). Measurement unit: micrograms (μg).

    Time frame: 24 hours after surgery

  5. Baseline, then assess NRS scores (visceral pain, incision pain, shoulder pain) at 30 min, 1 h, 3 h, 6 h, 12 h, 24 h, 48 h, and 72 h after the first dose.

    Time frame: 0-72 hours after surgery

  6. Use of rescue pain medication: cumulative usage of rescue pain medication (morphine injection mg) at 072h after the first dose

    Time frame: 0-72 hours after surgery

  7. The proportion of patients needing rescue pain relief within 72 hours after the first dose and the total amount of rescue medication used

    Time frame: 0-72 hours after surgery

  8. Incidence of nausea, vomiting, and PONV within 72 hours after the first dose

    Time frame: 0-72 hours after surgery

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Dec 2027, 15 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2026
First posted
Sep 17, 2026
StartEst.
Sep 2026
Primary completionEst.
Dec 2027
CompletionEst.
Dec 2027
Last update
Sep 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07826806
Responsible party
Sponsor
First posted
Sep 17, 2026
Start date
Sep 2026 (estimated)
Primary completion
Dec 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 17, 2026

Study contacts

Ping Chen, MD
Contact
sly178604@126.com
13821017600

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anrikefon

Start the discussion